UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000038103 |
|---|---|
| Receipt number | R000043418 |
| Scientific Title | Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure |
| Date of disclosure of the study information | 2019/09/26 |
| Last modified on | 2019/09/26 09:45:56 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure
Acronym
Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure
Scientific Title
Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure
Scientific Title:Acronym
Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure
Region
| Japan |
Condition
Condition
type2 diabetes
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
In this study, SGLT 2 inhibitor was administered and the effectiveness to reduce body weight was examined, not to lower the blood glucose level of type 2 diabetic patients with mild renal failure.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
HbA1c and body weight
Key secondary outcomes
We compared eGFR> 60 with normal kidney function, eGFR <60 as mild renal failure and comparing changes in body weight change with the two groups of HbA1c.
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 85 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) Outpatients
2) over 20 years old
3) T2DM
4) eGFR over 15 mL/min/1.73 m2
5) Diet and exercise therapies are well performed
6) Patients who are suspected good-compliant
7) Understanding of the study procedures and agreement to participate in the study
Key exclusion criteria
1) Patients suspected of having secondary diabetes (ex. endocrine disease, drug-induced or liver disease)
2) Females who are pregnant or who intend to become pregnant within the study
3) Severe hepatic disease, malignancy, a history of gastrectomy and/or positive for HIV
4) Contraindication with SGLT2 inhibitors
5) Patient who disqualified from the study by the investigator for any reason other than given above.
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | Shinji |
| Middle name | |
| Last name | Taneda |
Organization
Manda Memorial Hospital
Division name
Diabetes Center
Zip code
060-0062
Address
Minami 2, Nishi 1, Chuo-ku, Sapporo
TEL
011-231-4032
taneda@manda.or.jp
Public contact
Name of contact person
| 1st name | Yasuhiro |
| Middle name | |
| Last name | Iijima |
Organization
Manda Memorial Hospital
Division name
Diabetes Center
Zip code
060-0062
Address
Minami 2, Nishi 1, Chuo-ku, Sapporo
TEL
011-231-4032
Homepage URL
yasuhiro.iijima1203@gmail.com
Sponsor or person
Institute
Manda Memorial Hospital
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Manda Memorial Hospital
Address
Minami 2, Nishi 1, Chuo-ku, Sapporo
Tel
011-231-4032
taneda@manda.or.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
萬田記念病院（北海道）
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 09 | Month | 26 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
80
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2018 | Year | 04 | Month | 01 | Day |
Date of IRB
| 2018 | Year | 10 | Month | 28 | Day |
Anticipated trial start date
| 2018 | Year | 10 | Month | 28 | Day |
Last follow-up date
| 2019 | Year | 04 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
none
Management information
Registered date
| 2019 | Year | 09 | Month | 26 | Day |
Last modified on
| 2019 | Year | 09 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043418
